Compare MATH & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MATH | ELTX |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.4M | 158.5M |
| IPO Year | N/A | N/A |
| Metric | MATH | ELTX |
|---|---|---|
| Price | $2.66 | $9.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 115.0K | 105.8K |
| Earning Date | 12-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $44,567,257.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.63 | ★ N/A |
| Revenue Growth | ★ 165.86 | N/A |
| 52 Week Low | $0.88 | $4.60 |
| 52 Week High | $4.17 | $12.62 |
| Indicator | MATH | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.92 | 47.43 |
| Support Level | $2.75 | $7.87 |
| Resistance Level | $3.03 | $9.55 |
| Average True Range (ATR) | 0.22 | 0.49 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 30.43 | 65.48 |
Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.